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An Atypical Case of Hemolytic Anemia
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Introduction

Images

It is common practice to prophylactically initiate patients that are at high risk for
TLS on Rasburicase. As TLS is a significant outcome of chemotherapy causing
end-organ damage, it is often not feasible to await test results to initiate
prophylaxis. The reported prevalence of rasburicase-induced hemolytic anemia is
less than 1%.(3-4)Few cases reports are noted, and hemolysis has been observed
during clinical trials. There are 17 reported cases of acute hemolytic anemia or
methemoglobinemia after the administration of rasburicase. 12 of those patients
were G6PD deficient, 2 patients had normal G6PD activity, and 3 patients had
unknown G6PD status or suspected G6PD deficiency(5). Given the lack of
significant clinical studies in addition to most studies not including ethnic groups
that are at high risk for G6PD deficiency, the representation of morbidity and
mortality remains slim. It remains a standard of care to give Rasburicase in
anticipation of TLS syndrome even in institutions with a high prevalence of G6PD
deficiency within their community. Currently, the use of rasburicase in patients
with G6PD deficiency is contraindicated with a black box warning from the
FDA(6). Recommendations should be made to review the standard of care and
possibly implement testing with a faster turnaround in communities that have a
higher representation of G6PD deficiency.

Tumor lysis syndrome (TLS) is a well-known oncologic emergency that can
cause significant morbidity and mortality in highly proliferative tumors such as
Lymphomas or Leukemias. Rasburicase is a recombinant urate oxidase enzyme
that converts uric acid to allantoin, which is 5 to 10 times more soluble in urine
than uric acid (1) It is recommended by the 2008 American Society of Clinical
Oncology (ASCO) Guidelines for the Management of Pediatric and Adult Tumor
Lysis Syndrome as the initial management of patients with high risk of
developing TLS and in patients with intermediate risk if hyperuricemia occurs
despite allopurinol prophylaxis(2). G6PD-deficient patients are unable to break
down hydrogen peroxide that results from the oxidation of uric acid to allantoin
therefore increasing their likelihood of developing hemolytic anemia with
rasburicase.

Case Presentation
A 68-year-old male with PMH of progressive relapsed CLL/SLL presented to the
inpatient Oncology unit for initiation of chemotherapy (Venetoclax- selective, small
molecule inhibitor of BCL2). The patient had no acute complaints save mild tension
headache. He was initiated on Venetoclax and given prophylactic 3mg Rasburicase as
well as IV fluids the same day. The following day the patient had fatigue, shortness of
breath and an increase in oxygen requirements requiring nasal cannula which
escalated to HFNC. CXR showed evidence of mild pulmonary which was relieved
with Lasix. He had a subsequent episode of mild oxygen desaturation the following
day with severe shortness of breath and fatigue. Work-up was significant for an ABG
with mild decrease in PO2 and normal oxygen saturations. CBC revealed a 2g/dl
hemoglobin drop which initially was not adequately responsive to 2 units of packed
red blood cell transfusion. Hemolysis workup subsequently revealed an increased
LDH of 1151 U/L and decreased haptoglobin (<30 mg/dL).. There was evidence of
hemolysis on the pretransfusion specimen and the patient's G6PD screen was positive
thereafter. The hemolytic anemia was deemed likely due to Rasburicase. Rasburicase
was substituted with allopurinol and the patient was supported with serial monitoring
of complete blood count and chemistry profile, supplemental oxygen therapy,
transfusion of packed red blood cells, and vigorous hydration with no further episodes
of hemolysis. Recommendations were made to screen for G6PD deficiency in all
patients with anticipated need for rasburicase.

Discussion

Fig. 1. 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for
Rasburicase Therapy in the Context of G6PD Deficiency Genotype
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Fig. 2. Rasburicase mechanism of action in the catabolic pathway or purines

